Lisocabtagene Maraleucel
BMS
['lymsm', 'dlbcl', 'cart,(-cartitude)']
lisocel #cart setting the benchmark for what to expect from second line therapy for non transplant eligible patients with dlbcl #lymsm with cr 54% and no grade 4/5 crs or neurotoxicity #asco22 
A hematologist @MoffittNews with interest in #lymsm. Tweets are not endorsements, and not medical advice.